No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RGNX250117P15000
- 7.57
- 0.000.00%
15min DelayTrading Dec 19 10:44 ET
0.00High0.00Low
0.00Open7.57Pre Close0 Volume330 Open Interest15.00Strike Price0.00Turnover257.57%IV-1.23%PremiumJan 17, 2025Expiry Date7.66Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7606Delta0.0629Gamma0.91Leverage Ratio-0.0295Theta-0.0073Rho-0.69Eff Leverage0.0060Vega
Intraday
- 5D
- Daily
News
PepGen Stock Craters 35% on FDA Clinical Hold
RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
Express News | Regenxbio Inc - to Offer and Sell Shares up to $150 Million
Express News | Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners
Apollo Global Management, Workday to Join S&P 500